Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma

References

• Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005;23: 4117–26.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open- label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;12:1013–22.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–86.
   PubMed Web of Science ®Google Scholar
• Sonet A, Bosly A. Rituximab and chemotherapy in diffuse large B-cell lymphoma. Expert Rev Anticancer Ther 2009;9:719–26.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–16.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010;116:2040–5.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Schoder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 2010;28:1896–903.
   PubMed Web of Science ®Google Scholar
• Greb A, Bohlius J, Trelle S, Schiefer D, De Souza CA, Gisselbrecht C, et al. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma – results of a comprehensive meta-analysis. Cancer Treat Rev 2007;33:338–46.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–94.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006;24:995–1007.
   PubMed Web of Science ®Google Scholar
• Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011;29:1844–54.
   PubMed Web of Science ®Google Scholar
• Yang DH, Min JJ, Song HC, Jeong YY, Chung WK, Bae SY, et al. Prognostic significance of interim 18F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Eur J Cancer 2011;47:1312–8.
   PubMed Web of Science ®Google Scholar
• Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: Poor predictive value of international harmonization project interpretation. J Nucl Med 2011;52:386–92.
   PubMed Web of Science ®Google Scholar
• Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome. Blood 2005;106:1376–81.
   PubMed Web of Science ®Google Scholar
• Mikhaeel NG, Hutchings M, Fields PA, O’Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16: 1514–23.
   PubMed Web of Science ®Google Scholar
• Yoo C, Lee DH, Kim JE, Jo J, Yoon DH, Sohn BS, et al. Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol 2011;90:797–802.
   PubMed Web of Science ®Google Scholar
• Pregno P, Chiappella A, Bello M, Botto B, Ferrero S, Franceschetti S, et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood 2012;119:2066–73.
   PubMed Web of Science ®Google Scholar
• Wu X, Dastidar P, Pertovaara H, Korkola P, Jarvenpaa R, Rossi M, et al. Early treatment response evaluation in patients with diffuse large B-cell lymphoma – a pilot study comparing volumetric MRI and PET/CT. Mol Imaging Biol 2011;13: 785–92.
   PubMed Web of Science ®Google Scholar
• Schoder H, Noy A, Gonen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:4643–51.
   PubMed Web of Science ®Google Scholar
• Watanabe R, Tomita N, Takeuchi K, Sakata S, Tateishi U, Tanaka M, et al. SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma. Leuk Lymphoma 2010;51: 279–83.
   PubMed Web of Science ®Google Scholar
• Ngeow JY, Quek RH, Ng DC, Hee SW, Tao M, Lim LC, et al. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. Ann Oncol 2009; 20:1543–7.
   PubMed Web of Science ®Google Scholar
• Nguyen NC, Kaushik A, Wolverson MK, Osman MM. Is there a common SUV threshold in oncological FDG PET/CT, at least for some common indications?A retrospective study. Acta Oncol 2011;50:670–7.
   PubMed Web of Science ®Google Scholar
• Wilder RB, Rodriguez MA, Ha CS, Pro B, Hess MA, Cabanillas F, et al. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Cancer 2001;91:2440–6.
   PubMed Web of Science ®Google Scholar
• Fuss M. Strategies of assessing and quantifying radiation treatment metabolic tumor response using F18 FDG positron emission tomography (PET). Acta Oncol 2010;49:948–55.
   PubMed Web of Science ®Google Scholar
• Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging 1999;2:159–71.
   PubMedGoogle Scholar
• Schaefer NG, Strobel K, Taverna C, Hany TF. Bone involvement in patients with lymphoma: The role of FDG-PET/CT. Eur J Nucl Med Mol Imaging 2007;34:60–7.
   PubMed Web of Science ®Google Scholar
• Song MK, Chung JS, Shin HJ, Lee SM, Lee SE, Lee HS, et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol 2012; 91:697–703.
   PubMed Web of Science ®Google Scholar